Screening for liver cancer: Results of a randomised controlled trial in Qidong, China

Journal of Medical Screening

Volumn 10, Issue 4, 2003, Pages 204-209

  Chen, J G ^b   Parkin, D M ^a   Chen, Q G ^c   Lu, J H ^b   Shen, Q J ^c   Zhang, B C ^b   Zhu, Y R ^c  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b QIDONG LIVER CANCER INSTITUTE   (China)

^c MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN;

ADULT; ARTICLE; CANCER CYTODIAGNOSIS; CANCER GRADING; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE CARRIER; FOLLOW UP; HEALTH PROGRAM; HEPATITIS B VIRUS; HIGH RISK POPULATION; HUMAN; LIVER CARCINOMA; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; PROTEIN DETERMINATION; RANDOMIZED CONTROLLED TRIAL; SCREENING TEST; SURVIVAL RATE;

ADULT; CHINA; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LIVER NEOPLASMS; MASS SCREENING; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0346495966     PISSN: 09691413     EISSN: None     Source Type: Journal    
DOI: 10.1258/096914103771773320     Document Type: Article

References (46)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2:533-43.
2. National Cancer Control Office, Nanjing Institute of Geography. Atlas of Cancer Mortality in the People's Republic of China, Shanghai: China Map Press, 1979.
3. Parkin DM, Whelan SL, Ferlay J, et al. Cancer Incidence in Five Continents Vol VII. IARC Sci Pub No 143, Lyon: IARC, 1997:322-5.
4. Lu JH, Chen JG, Ni ZP, et al. HBsAg carriers and hepatocellular carcinoma: a ten-year follow-up. Chin J Prev Med 1988;22:259-62.
5. Lu JH, Chen JG, Ni ZP, et al. A twenty-two prospective study on HBsAg carrier state and primary liver cancer in a community, Jiangsu. Chin Prev Med 2002;3:101-4.
6. Egner PA, Wang JB, Zhu YR, et al. Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci USA 2001;98:14601-6.
7. Pisani P, Parkin DM, Munoz N, Ferlay J. Cancer and infection: estimates of the attributable fraction in 1990. Cancer Epidemiol Biomarkers Prev 1997;6:387-400.
8. Berrino R, Capocaccia R, Esteve J, et al. Survival of Cancer Patients in Europe: the EUROCARE-2 Study. IARC Sci Pub No 151, Lyon: IARC, 1999:1:572.
9. Sankaranarayanan R, Black RJ, Parkin DM. Cancer Survival in Developing Countries. IARC Sci Pub No 145, Lyon: IARC, 1998:1:173.
10. Sheu JC, Sung JL, Chen DS, et al. Growth rates of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterol. 1985;89:259-66.
11. Columbo M. Early diagnosis of hepatocellular carcinoma in Italy. J Hepatol 1992;14:401-3.
12. Tang ZY, Yu YQ, Zhou XD, et al. Subclinical hepatocellular carcinoma: an analysis of 391 patients. J Surg Oncol Suppl 1993;3:55-8.
13. Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994;20:65-71.
14. Oka H, Tamori A, Kuroki T, et al. Prospective study of a-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatol 1994;19:61-6.
15. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatol 1995;22:432-38.
16. Zoli M, Magalotti D, Bianchi G, et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78:977-85.
17. Chalasani N, Horlander JC, Said A, et al. Screening for hepatocellular carcinoma in patients with advanced cirrhosis. Am J Gastroenterol 1999;94:2988-93.
18. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, et al. NIH conference. Hepatocellular carcinoma. Ann Intern Med 1988;108:390-401.
19. McMahon BJ, London T. Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst 1991;83:916-19.
20. Zhu YR, Chen JG, Huang XY. Hepatocellular carcinoma in Qidong County. In: Tang ZY, Wu MC, Hsia RS, eds. Primary liver Cancer. Berlin: Springer, 1989:202-24.
21. Zhu YR, Lu PX. Clinical implication of AFP serosurvey. Chin J Oncol 1983;5:38-40.
22. Zhang BC, Wang MR, Chen JG, et al. Analysis of patients with primary liver cancer detected (I) at mass screening and (II) during the follow-up period in a high risk population. Chin J Oncol 1994;21:489-91.
23. Chen JG, Sankaranrayanan R, Li WG, et al. Population-based survival analysis of primary liver cancer in a high-incidence area - Qidong, China during 1972-1991. Chin J Prev Med 1997;31:149-52.
24. Chen JG, Zhang BC, Jiang YH, et al. Study on screening for primary liver cancer in high risk population of an endemic area. Chin J Prev Med 1991;25:326-28.
25. Li WG, Yu YH, Shen ZC, et al. China, Qidong County. In: Parkin DM, Muir CS, Whelan SL, et al, eds (1992) Cancer Incidence in Five Continents, Vol. VI, IARC Scientific Publications No. 120, Lyon: IARC, 432-35.
26. Statistics and Epidemiology Research Corporation. EGRET (Epidemiological Graphics Estimation and Testing Package) Manual, third revision. Seattle: Statistics and Epidemiology Research Corporation, 1992.
27. Chen JG, Li WG, Shen ZC, et al. Analysis on expectancy life of inhabitants in Qidong, 1974-1994. Chin J Health Stat 1996;13:37-9.
28. Zhang SP, Wang NJ. Clinical and pathological features of primary of hepatocellular carcinoma in 26 patients survived over 10 years after operation. Chin J Pathol 1992;21:290-292.
29. Tang ZY, Yang BH. Secondary prevention of hepatocellular carcinoma. J Gastroenterol Hepatol, 1995;10:683-90.
30. Chen JG. The selection of high risk population for liver cancer: the feasibility of mass screening using alpha-fetoprotein. In: Tumour Control. Beijing: Chin Sci Tech Press, 1989:116-19.
31. Chen TH, Chen CJ, Yen MF, et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 2002;98:257-61.
32. Yang B, Zhang B, Xu Y, et al. Prospective study of early detection for primary liver cancer. J Cancer Res Clin Oncol 1997;123:357-60.
33. Haydon GH, Hayes PC. Screening for hepatocellular carcinoma. Eur J Gastroenterol Hepatol 1996;8:856-60.
34. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatol 1998;27:273-8.
35. Brown RS, Scharschmidt BF. Liver cancer. In: Kramer BS, Gohagan JK, Prorok PC, eds. Cancer Screening: Theory and Practice. New York: Marcel Dekker Inc., 1999:299-327.
36. Sherman M. Screening for hepatocellular carcinoma. Bailliere's Clin Gastroenterol 1999;13:623-35.
37. Sherman M. Screening for hepatocellular carcinoma. Semin Oncol 2001a;28:450-9.
38. Balondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001;48(2):251-9.
39. McMahon BJ, Bulkow L, Harpster A, et al. Screening for hepatocellular carcinoma in Alaska Native Infected with chronic hepatitis B: a 16-year population-based study. Hepatology 2000;32:842-6.
40. Zhang B, Yang B. Combined alpha-fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 1999;6:108-10.
41. Yoshino M. Growth kinetics of hepatocellular carcinoma. Jpn J Clin Oncol 1983;13;45-52.
42. Sherman M. Alphafetoprotein: an obituary. J Hepatol 2001;34:603-5.
43. Livraghi T, Bolondi L, Buscarini L, et al. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. J Hepatol, 1995;22:522-6.
44. Mima S, Sekiya C, Kanagawa H, et al. Mass screening for hepatocellular carcinoma: experience in Hokkaido, Japan. J Gastroenterol Hepatol 1994;9:361-5.
45. Moss SM. Case-control studies of screening. Int J Epidemiol 1991;20:1-6.
46. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study group. N Engl J Med 1997;336:1855-9.